Radioactive drug targets tough tumors in early trial
NCT ID NCT07232407
First seen Nov 18, 2025 · Last updated Jun 19, 2026 · Updated 25 times
Summary
This early-stage study tests a radioactive drug called lutetium BL-ARC001 in 22 people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. Participants receive the drug by IV every 6 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Cancer Hospital
RECRUITINGChengdu, Sichuan, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutetium [177Lu] BL-ARC001 (a radioactive drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for advanced gastrointestinal and other solid tumors that are hard to treat.
What could go wrong
This is a very early Phase I trial with only 22 people, so it is mainly checking safety and dosing. The drug may not shrink tumors or could cause side effects like radiation damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.